Published in Ann Oncol on November 01, 2000
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer (2006) 2.57
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell (2017) 1.41
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol (2009) 1.38
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol (2011) 1.15
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs (2005) 1.11
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas. J Gastroenterol (2007) 1.10
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer (2008) 1.02
Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg (2008) 1.01
Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. PLoS One (2012) 0.99
Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol (2012) 0.94
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer (2005) 0.88
Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer (2015) 0.86
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol (2010) 0.83
Escin Chemosensitizes Human Pancreatic Cancer Cells and Inhibits the Nuclear Factor-kappaB Signaling Pathway. Biochem Res Int (2013) 0.81
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer (2003) 0.79
Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Med (2015) 0.79
Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2015) 0.77
Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates. F1000Res (2015) 0.77
Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. Expert Opin Investig Drugs (2015) 0.76
Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Pancreas (2017) 0.75
Triplet cytotoxic chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced pancreatic cancer. Oncol Lett (2015) 0.75
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int J Mol Sci (2017) 0.75
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet (1998) 4.16
Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A (1997) 3.79
Persistence of man-made mineral fibres (MMMF) and asbestos in rat lungs. Ann Occup Hyg (1987) 2.92
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol (2005) 2.88
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Chemical composition of the peptidoglycan-free cell walls of methanogenic bacteria. Arch Microbiol (1978) 2.79
Alterations of skeletal muscle in chronic heart failure. Circulation (1992) 2.58
Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg (2001) 2.49
High mobility group protein 2 functionally interacts with the POU domains of octamer transcription factors. EMBO J (1995) 2.48
Evidence that HERV-K is the endogenous retrovirus sequence that codes for the human teratocarcinoma-derived retrovirus HTDV. Virology (1993) 2.32
Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg (1998) 2.24
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum (1994) 2.19
Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia (2004) 2.08
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
Interstitial and terminal deletions of the long arm of chromosome 4: further delineation of phenotypes. Am J Med Genet (1988) 2.00
The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect (1993) 2.00
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J (2001) 1.83
Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol (1989) 1.81
Faecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiency. Gut (1998) 1.81
Pretherapeutic laparoscopic staging in advanced gastric carcinoma. Endoscopy (1999) 1.76
Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg (1994) 1.75
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol (1998) 1.74
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology (2011) 1.70
Mucormycoses. Mycoses (2001) 1.70
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Cell wall polymers in Archaea (Archaebacteria). Cell Mol Life Sci (1998) 1.67
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer (1993) 1.63
Carcinogenicity of cadmium chloride aerosols in W rats. J Natl Cancer Inst (1983) 1.63
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58
Further delineation of the Baller-Gerold syndrome. Am J Med Genet (1993) 1.56
Steatorrhoea: you cannot trust your eyes when it comes to diagnosis. Lancet (1996) 1.54
The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol (1981) 1.53
CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci (2000) 1.52
[Haemophilus-pleuropneumonia in swine. V. Pathomorphology]. Schweiz Arch Tierheilkd (1973) 1.52
Analysis and nucleotide sequence of the genes encoding the surface-layer glycoproteins of the hyperthermophilic methanogens Methanothermus fervidus and Methanothermus sociabilis. Eur J Biochem (1991) 1.46
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol (1997) 1.46
Pyrodictium gen. nov., a New Genus of Submarine Disc-Shaped Sulphur Reducing Archaebacteria Growing Optimally at 105°C. Syst Appl Microbiol (1983) 1.46
Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol (1989) 1.44
Magnetic resonance imaging of normal and pathological white matter maturation. Pediatr Radiol (1988) 1.43
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology (1995) 1.40
Routine application of the polymerase chain reaction for detection of Mycobacterium tuberculosis in clinical samples. J Clin Pathol (1995) 1.40
Diagnosis and treatment of AL amyloidosis. Clin Nephrol (2000) 1.40
Purification and use of Methanobacterium wolfei pseudomurein endopeptidase for lysis of Methanobacterium thermoautotrophicum. J Bacteriol (1987) 1.40
The full-scale PACS archive. A prerequisite for the filmless hospital. Acta Radiol (1996) 1.39
Increases of sICAM-1 during neutropenic pneumonia in leukemic patients. Leukemia (1997) 1.39
Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol (1995) 1.39
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat (2003) 1.39
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Human autologous mixed lymphocyte reactivity is primarily specific for xenoprotein determinants adsorbed to antigen-presenting cells during rosette formation with sheep erythrocytes. J Exp Med (1982) 1.37
The amino acid sequence of the peptide moiety of the pseudomurein from Methanobacterium thermoautotrophicum. Arch Microbiol (1979) 1.37
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia (2003) 1.37
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res (1994) 1.36
Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients. Infection (1985) 1.35
Aerobic and facultatively anaerobic cellulolytic bacteria from the gut of the termite Zootermopsis angusticollis. J Appl Microbiol (2002) 1.34
Immunological studies of the basis for the apathogenicity of simian immunodeficiency virus from African green monkeys. Proc Natl Acad Sci U S A (1990) 1.33
New developments in the treatment of gastric carcinoma. Semin Oncol (1990) 1.32
[Haemophilus-pleuropneumonia in swine. VI. Pathogenesis]. Schweiz Arch Tierheilkd (1973) 1.30
HERV-K: the biologically most active human endogenous retrovirus family. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.26
CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res (1999) 1.24
Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways. J Biol Chem (2000) 1.23
Homologous and illegitimate recombination in developing Xenopus oocytes and eggs. Mol Cell Biol (1993) 1.23
Renal complications in acute leukemias. Haematologica (1998) 1.23
A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer (1999) 1.23
High Pressure Enhances the Growth Rate of the Thermophilic Archaebacterium Methanococcus thermolithotrophicus without Extending Its Temperature Range. Appl Environ Microbiol (1988) 1.21
Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol (1999) 1.20
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer (2000) 1.19
Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res (2001) 1.19
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie (2003) 1.17
Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer (1995) 1.16
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol (1998) 1.14
Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer (2001) 1.13
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
[Occurrence and significance of swine diseases: Analysis of dissected material (1971-1973). IV. Pathology of the respiratory tract]. Schweiz Arch Tierheilkd (1976) 1.12
Hemicellulose-degrading bacteria and yeasts from the termite gut. J Appl Bacteriol (1996) 1.12
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia (2003) 1.11
Circular single stranded phage M13-DNA as a template for DNA synthesis in protein extracts from Xenopus laevis eggs: evidence for a eukaryotic DNA priming activity. Nucleic Acids Res (1982) 1.11
Primary structure of the heterosaccharide of the surface glycoprotein of Methanothermus fervidus. J Biol Chem (1993) 1.10
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol (1996) 1.09
Orbital metastases in breast cancer: report of two cases and review of the literature. J Cancer Res Clin Oncol (2004) 1.09
Application of chromosomal microarray in the evaluation of abnormal prenatal findings. Clin Genet (2012) 1.08
Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol (2000) 1.07
Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol (2001) 1.07
Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat (2002) 1.07
Answering patients' needs: oral alternatives to intravenous therapy. Oncologist (2001) 1.06
Redox-mediated decolorization of synthetic dyes by fungal laccases. Appl Microbiol Biotechnol (2002) 1.06
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol (2004) 1.06
Rapid isolation of single microbial cells from mixed natural and laboratory populations with the aid of a micromanipulator. Syst Appl Microbiol (1999) 1.06